Paratek Pharmaceuticals, Inc. to Participate in JMP Securities Life Science Conference
June 14 2017 - 7:30AM
Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) today announced that
Evan Loh, MD, President, Chief Operating Officer and Chief Medical
Officer, will participate in a panel discussion at the JMP
Securities Life Science Conference on Wednesday, June 21. The panel
titled Antibiotics will begin at 12:30 p.m. ET. The conference is
being held at the St. Regis New York in New York City. Paratek is a
biopharmaceutical company focused on the development and
commercialization of innovative therapies based upon tetracycline
chemistry.
About ParatekParatek Pharmaceuticals,
Inc. is a biopharmaceutical company focused on the development
and commercialization of innovative therapies based upon its
expertise in novel tetracycline chemistry. Paratek's lead product
candidate, omadacycline, when approved, will be the first in a new
class of tetracyclines known as aminomethylcyclines, with
broad-spectrum activity against Gram-positive, Gram-negative and
atypical bacteria. Omadacycline is a new, once-daily oral and
intravenous broad-spectrum antibiotic being developed for use as
empiric monotherapy for patients suffering from serious
community-acquired bacterial infections, such as acute bacterial
skin and skin structure infections, community-acquired bacterial
pneumonia, urinary tract infections, and other
community-acquired bacterial infections, particularly when
antibiotic resistance is of concern to prescribing
physicians. Omadacycline has been granted Qualified Infectious
Disease Product designation and Fast Track status by the U.S.
Food and Drug Administration for the target indications.
In June 2016, Paratek announced positive efficacy data in a
Phase 3 registration study in acute bacterial skin and skin
structure infections (ABSSSI) demonstrating the efficacy and
general safety and tolerability of intravenous (IV) to once-daily
oral omadacycline compared to linezolid. In April 2017,
Paratek announced positive efficacy data in a Phase 3 registration
study in community-acquired bacterial pneumonia (CABP)
demonstrating the efficacy and general safety and tolerability of
IV to once-daily oral omadacycline compared to moxifloxacin. A
Phase 3 registration study in ABSSSI comparing once-daily oral-only
dosing of omadacycline to twice-daily oral-only dosing of linezolid
was initiated in August 2016. This study completed enrollment
in May 2017 and top-line data are expected in mid-July.
The Company plans to submit its new drug application (NDA) in the
U.S. as early as the first quarter of 2018 with an EMA submission
later in 2018. In addition to its Phase 3 program for omadacycline,
a Phase 1B study in uncomplicated urinary tract infections (UTI)
was initiated in May 2016 and positive top-line PK
proof-of-principle data was reported in November 2016. The
Company plans to begin enrolling patients in a proof-of-concept
Phase 2 study of omadacycline in acute pyelonephritis, the most
common subset of complicated urinary tract infections, as early
as December 2017. In October 2016, Paratek announced a
research agreement with the U.S. Department of Defense to
explore the utility of omadacycline against pathogenic agents
causing infectious diseases of public health and biodefense
importance including plague and anthrax. In April
2017, Paratek Bermuda Ltd., a wholly-owned subsidiary of the
Company, and Zai Lab (Shanghai) Co., Ltd., entered into a
License and Collaboration Agreement. Under the terms of the
Agreement, the Company granted Zai an exclusive license to develop,
manufacture, and commercialize omadacycline in the
People’s Republic of China, Hong
Kong, Macau and Taiwan, for all human therapeutic
and preventative uses, other than biodefense. Paratek's second
Phase 3 product candidate, sarecycline, is a well-tolerated,
once-daily oral, narrow spectrum tetracycline-derived antibiotic
with potent anti-inflammatory properties for the potential
treatment of acne and rosacea in the community
setting. Allergan owns the U.S. rights for the development and
commercialization of sarecycline. Paratek retains all ex-U.S.
rights. Allergan and Paratek reported positive results
from two identical Phase 3 registration studies of sarecycline for
the treatment of moderate to severe acne vulgaris in March
2017. Allergan has publicly announced plans to submit an NDA
in the U.S. in the second half of 2017. For more information,
visit www.paratekpharma.com.
CONTACTS:
Media Relations:
Michael Lampe
(484) 575-5040
michael@scientpr.com
Investor Relations:
Hans Vitzthum
LifeSci Advisors, LLC.
212-915-2568
Paratek Pharmaceuticals (NASDAQ:PRTK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Paratek Pharmaceuticals (NASDAQ:PRTK)
Historical Stock Chart
From Apr 2023 to Apr 2024